menu Search
Krijenta

Krijenta

linagliptin

Manufacturer:

Fredun Pharmaceuticals

Distributor:

Khriz Pharma
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
Type 2 DM in adults as adjunct to diet & exercise to improve glycaemic control as: Monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy w/ other medicinal products for treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
Click to view Krijenta detailed prescribing information
Dosage/Direction for Use
5 mg once daily.
Click to view Krijenta detailed prescribing information
Overdosage
View Krijenta overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Click to view Krijenta detailed prescribing information
Special Precautions
Not to be used in patients w/ type 1 diabetes or for treatment of diabetic ketoacidosis. Associated w/ risk of developing acute pancreatitis. Discontinue treatment if pancreatitis is suspected; do not restart if acute pancreatitis is confirmed. Post-marketing reports of bullous pemphigoid. Discontinue treatment if bullous pemphigoid is suspected. Hypoglycaemia when used in combination w/ sulphonylurea &/or insulin. Lack of clinical experience in patients w/ hepatic impairment. Preferable to avoid use during pregnancy. Discontinue breast-feeding or discontinue/abstain from therapy during breast-feeding. Safety & efficacy have not yet been established in childn & adolescents. Caution in patients >80 yr.
Click to view Krijenta detailed prescribing information
Use In Pregnancy & Lactation
Click to view Krijenta detailed prescribing information
Adverse Reactions
Increased lipase. Hypoglycaemia (w/ metformin & sulphonylurea).
Click to view Krijenta detailed prescribing information
Drug Interactions
Decreased steady-state AUC & Cmax w/ rifampicin (potent inducer of P-gp & CYP3A4).
Click to view Krijenta detailed prescribing information
Storage
View Krijenta storage conditions for details to ensure optimal shelf-life.
Description
View Krijenta description for details of the chemical structure and excipients (inactive components).
Action
View Krijenta mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Regulatory Classification
Rx
Presentation/Packing
Form
Krijenta tab 5 mg
Packing/Price
30's